229 related articles for article (PubMed ID: 28731168)
1. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
3. [Establish mouse osteoblast -osteoclast cell co-culture system in a Transwell chamber].
Mo GY; Zhang SC; Li YX; Guo HZ; Guo DQ; Li DX; Tang YC; Mo L; Luo PJ; Ma YH
Zhongguo Gu Shang; 2018 Mar; 31(3):241-247. PubMed ID: 29600675
[TBL] [Abstract][Full Text] [Related]
4. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
5. IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.
Singh K; Piprode V; Mhaske ST; Barhanpurkar-Naik A; Wani MR
J Immunol; 2018 Jan; 200(2):595-606. PubMed ID: 29203513
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
[TBL] [Abstract][Full Text] [Related]
7. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
8. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
[TBL] [Abstract][Full Text] [Related]
10. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
13. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
[TBL] [Abstract][Full Text] [Related]
14. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity.
Furuya Y; Inagaki A; Khan M; Mori K; Penninger JM; Nakamura M; Udagawa N; Aoki K; Ohya K; Uchida K; Yasuda H
J Biol Chem; 2013 Feb; 288(8):5562-71. PubMed ID: 23319583
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
18. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
20. Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain.
Kusumi A; Sakaki H; Kusumi T; Oda M; Narita K; Nakagawa H; Kubota K; Satoh H; Kimura H
J Bone Miner Metab; 2005; 23(5):373-81. PubMed ID: 16133687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
